An expert is one who knows more and more about less and less until he knows absolutely everything about nothing

Sunday, March 6, 2016

Centre for Addiction and Mental Health..CAMH

About CAMH Research
The Centre for Addiction and Mental Health (CAMH) is the leading mental health and addictions research facility in Canada, and one of the largest in the world. Research at CAMH is an integrated part of the organization. We share CAMH’s vision, mission, and values.
Our research program has three pillars:
• The Campbell Family Mental Health Research Institute, with a focus on brain science
• Clinical research
• Social and epidemiological research
AffiliationsAs a teaching hospital, all CAMH scientists hold cross-appointments with the University of Toronto. CAMH is a designated WHO/PAHO Collaborating Centre in Addictions and Mental Health.
contact info
Research Services Office​
33 Russell St., T100
Toronto, ON M5S 2S1
The CAMH Research Strategic Plan​, launched in November 2013, sets out the roadmap for our research program for the future, in alignment with VISION2020, CAMH’s strategic plan
 Read the full report ​or view a snapshot of the plan below.
The Centre for Addiction and Mental Health houses state-of-the art facilities to conduct research. Some of our core facilites include:
Positron Emission Tomography
Magnetic Resonance Imaging
Alcohol and Gambling Lab
Confocal Microscope
CAMH by the Numbers​
CAMH is home to the largest mental health and addictions research facility in Canada. We have more than 100 scientists, nearly 500 research staff and more than 150 trainees.
Research grants/contracts awarded in 2011-12: 223
External research funding in 2011-12: $40,006,075
Number of papers published in 2011: 458
Number of patents issued in 2011: 4
We gratefully acknowledge the support of our major funders:
  • Canadian Institutes of Health Research ​
  • CAMH donors and the CAMH Foundation, with special thanks to: Campbell Family, Temerty Family, Fidani Family, Raymond Chang, Tanenbaum Family
  • U.S. National Institutes of Health
  • Health Canada
  • Ministry of Health and Long-term Care
  • Canada Foundation for Innovation
  • Ministry of Economic Development and Innovation
  • Public Health Agency of Canada
Some of the other partners we currently receive support from include:
Citizenship and Immigration Canada  ​
NARSAD: The Brain and Behaviour Fund
American Foundation for Suicide Prevention
Ontario Mental Health Foundation
AFP Innovation Fund (Alternative Funding Program)
Social Sciences and Humanities Research Council of Canada
Bristol-Meyers Squibb
Ontario Problem Gambling Research Centre
Parkinson Society of Canada
Janssen-Ortho Inc.
Pfizer Canada Inc.
Mental Health Commission of Canada
Network of Centres of Excellence Research Awards – AUTO 21
Social and Enterprise Development Innovations (SEDI)
Schizophrenia Society of Ontario
Ontario Lung Association
Ontario Power Generation
Heart and Stroke Foundation of Canada
American Psychiatric Association
American Foundation for Suicide Prevention
American Psychiatric Foundation
Ontario Tobacco Research Unit
Canadian Child Health Clinician Scientist Program
Scottish Rite Charitable Foundation of Canada
University of Minnesota
ECHO – Improving Women’s Health in Ontario
InterVivo Solutions Inc.
International Rett Syndrome Foundation
Office for Disability Issues
Ministry of Children and Youth Services
Rotman School of Management
Canadian Health Services Research Foundation
Dempster Family Foundation
TEVA Pharma
Ontario Brain Institute
St. Stephen’s Community House ​
Toronto Public Health
World Health Organization
American Psychology Law Society Division 41 ​
The Centre for Addiction and Mental Health (CAMH) was founded in 1998 as a result of the merger of the Clarke Institute of Psychiatry, the Addiction Research Foundation, the Donwood Institute, and the Queen Street Mental Health Centre.
Some research milestones by CAMH and its founding organizations include:
Dr. Philip Seeman discovers that the effectiveness of antipsychotic drugs is directly related to their ability to block the dopamine D2 receptor. This opens the way to a scientific explanation for the drugs’ reactions. His papers are among the most highly cited in the schizophrenia literature.
The Addiction Research Foundation (now part of CAMH) is named the first World Health Organization (WHO) Collaborating Centre in the field of drugs and alcohol. This international collaborative role continues today; in 2008, CAMH research underlies WHO’s adoption of the Global Strategy to Reduce the Harmful Use of Alcohol.
Addiction Research Foundation develops RIDE (Reduce Impaired Driving in Etobicoke) as a pilot project beginning Oct. 1, 1977. Today RIDE (now Reduce Impaired Driving Everywhere) is used by police across the country.
Opening of Canada’s first PET Centre (medical imaging) dedicated to research into mental illness. Over the following decade, CAMH’s PET Centre develops 12 of the 25 ligands (illuminating radiotracer agents) most commonly used in human neuroscience.
Merger of four organizations to form the Centre for Addiction and Mental Health (CAMH): Queen Street Mental Health Centre, Clarke Institute of Psychiatry, Donwood Institute, and Addiction Research Foundation – a pioneering move recognizing the interconnected nature of mental illness and addiction.
CAMH scientists identify a new variant of the gene that causes Rett syndrome, a serious neurodevelopmental disorder that affects almost exclusively females. The discovery is translated into a licensed diagnostic tool for the disease that is currently available to the public.
CAMH PET studies reveal that most antidepressants miss the key target – serotonin receptors – for treating clinical depression. The discovery establishes a standard that anti-depressants being developed for the market be 80 per cent effective in hitting this target.
Opening of the Krembil Family Epigenetics Laboratory at CAMH – the first psychiatric epigenetics lab in the world. Epigenetics explores the “switches” that turn genes on or off, for example, the impact of nutrition and stress.
CAMH opens Canada’s first pharmacogenetics clinic, dedicated to understanding the genetics of people’s response to psychiatric medication and the side-effects they experience. Its vision is a new era of personalized medicine for people living with all forms of mental illness and addiction.
CAMH researchers discover the first concrete genetic linkage to schizophrenia via a subtype of the disease called Deletion Syndrome (22qDS).
CAMH scientists demonstrate that mindfulness-based cognitive therapy provides equivalent protection against depressive relapse as traditional antidepressant medication.
CAMH scientists discover higher levels of a brain protein called monoamine oxidase A (MAO-A) in women after childbirth. This provides a possible explanation why post-partum blues and clinical depression occur, as MAO-A removes chemicals like serotonin that help maintain normal moods. Using this knowledge, scientists begin developing supplements to target this loss of nutrients, and lower the risk of post-partum depression.
Using brain imaging and genetics, CAMH scientists identify a variation of a gene that may play a role in late-onset Alzheimer’s disease.
CAMH launches first mobile research laboratory to study mental health and addictions in communities across Ontario. With a goal of improving prevention and treatment services, the mobile lab will visit and partner with local agencies in rural, remote and First Nations communities.
The Campbell Family Mental Health Research Institute at CAMH officially opens. The institute is dedicated to understanding brain structure and function to identify the causes and best treatments for mental illness and addictions.
CAMH opens the Temerty Centre for Therapeutic Brain Intervention. The centre aims to research innovative non-invasive brain stimulation treatments including: Repetitive Transcranial Magnetic Stimulation and Magnetic Stimulation Therapy.
CAMH opens the Tanenbaum Centre for Pharmacogenetics, a research collaborative focused on identifying genetic predictors to personalize the prescription of psychiatric drugs. This approach could help to determine which clients are more likely to respond to a given medication, who will experience side-effects, and if dose adjustments need to be considered.

The Research Ethics Board (REB) at the Centre for Addiction and Mental Health (CAMH) reviews research involving human participants, conducted under CAMH’s auspices, to ensure that it meets the highest ethical and scientific standards.
The REB has a diverse and experienced membership that includes scientists, clinicians, community members and those with specialized knowledge of law and ethics. The REB meets the requirements of the Tri Council Policy Statement and the International Committee on Harmonization of Good Clinical Practice. The Research Ethics Office provides support to the REB, ensures that initial and continuing review of human research is undertaken and provides educational programs for the research community.
For information on submitting protocols for review, see our Protocol Forms & Guidelinessection.
View CAMH’s Code of Research Integrity, approved by CAMH”s Research Executive Committee (updated Sept. 4, 2012).
Effective May 3, 2004, all applications for approval by the CAMH Research Ethics Board of protocols, amendments or renewals must be accompanied by evidence of successful completion of the Tri-Council Policy Statement (TCPS-2) tutorial which can be accessed through Researchers who have already completed the NIH course may also wish to take the new TCPS-2 course but this is not mandatory.
EACH member of the research team must complete the course and supply Research Ethics Office. of CAMH Research Ethics Office with a copy of their certificate of completion. This requirement applies independent of source of study funding, although applicants for NIH funds must, in addition, take the NIH course.
Investigators must fill out the CAMH “Final Report for the Research Ethics Board” form and provide it to the CAMH Research Ethics Office upon completion of each study approved by the CAMH REB. If the study has NOT been completed or terminated, and needs to be renewed, please fill out the CAMH Annual Renewal of Ethics Approval form.
If a study is to be conducted only with external grant funding, the protocol will not be reviewed until the investigator indicates that the funding application has been successful and funds have been awarded. Investigators are free to submit their protocols prior to notice of funding but they will not be reviewed until funding has been confirmed.
If your study will be externally funded, please submit three (3) copies of your contract OR grant, including the budget, with this protocol form.
If your study will be internally funded, please submit three (3) copies of the budget with this protocol form.​

Investigators are reminded that it is THEIR responsibility to renew Research Ethics Board approval on a regular basis.  Approvals are given for at most 12 months and must then be renewed.  If a study has finished recruitment and data analysis has been completed then a Final Report Form must be completed.  Please refer to link for forms.

Investigators are reminded that approvals from the Research Ethics Board (REB) for studies/amendments which involve application to Health Canada are conditional upon approval by Health Canada.  Therefore the study/amendment cannot be initiated until both approval from the REB and Health Canada have been obtained.
Effective immediately,scientists who wish to conduct PET Studies which involve a Clinical Trials Application to Health Canada must first obtain a completed form fromIrina Vitcu, PET Centre, prior to any REB submission.  This rule applies to both new protocols and study amendments.
  • Are you having trouble drafting a consent form for your research study?
  • Do you want to learn more about CAMH, Research Ethics Board consent requirements?
If so, please contact Susan Pilon ( to arrange to meet with her for consent form advice.

NEW:  Additional consent form information.  Please include in all consent forms the following information:
“As part of the Research Services Quality Assurance Program, this study may be monitored and/or audited by a member of the Quality Assurance Team.  Your research records and CAMH records may be reviewed during which confidentiality will be maintained as per CAMH policies and extent permitted by law”.
Please verify if your consent forms reflect recent changes in the phone extension of the REB Chair, Dr. Padraig Darby.  The new extension is 36876.

As an academic health science center, it is essential that CAMH and researcher and research personnel ensure that research is conducted in compliance with federal, provincial, local and institutional regulations in order to ensure the safety of research participants.  Compliance with Good Clinical Practice (GCP), which currently is the only international standard for conducting research, is important in ensuring the validity and credibility of research data by encompassing the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of human subject research studies.  GCP also provides assurance that the rights, safety, confidentiality and well-being of research participants are protected.
GCP training is a CAMH requirement and must be completed prior to REB submission.  Please contact the Research Training Coordinator for more information regarding CP training. Kindly send GCP certificates directly to the Training Coordinator and not to Research Ethics Office.


Post a Comment

About Blogger:

Hi,I,m Basim from Canada I,m physician and I,m interested in clinical research feild and web are more welcome in our professional website.all contact forwarded to

Let's Get Connected: Twitter | Facebook | Google Plus| linkedin


Subscribe to us